Oral magnesium supplementation improves glycaemic status in subjects with prediabetes and hypomagnesaemia: A double-blind placebo-controlled randomized trial
Guerrero-Romero F, Simental-Mendía LE, Hernández-Ronquillo G, Rodriguez-Morán M
Diabetes & metabolism · 66 citas
Cómo se estudió
- Diseño
- Ensayo controlado aleatorizado (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Marcadores de salud y funcionamiento
Quién lo pagó
- Financiación
- Financiación independiente
- Gobierno
- Instituto Mexicano del Seguro Social
Según 1 financiador declarado.
Publicación
- Publicado
- 2015-04-27 · Diabetes Metab · vol. 41 · número 3 · págs. 202–207
- Editorial
- Elsevier BV
- Citado
- 108 citas · más que el 98% de estudios similares · 9.8× el promedio de su campo
- Impacto
- Entre el 10 % más citado de su campo
- Referencias
- 49 trabajos
- Acceso
- De pago
- Áreas de investigación
- Magnesium in Health and Disease · Magnesium Alloys: Properties and Applications · Trace Elements in Health
- Palabras clave
- magnesium supplementation, hypomagnesemia, prediabetes, plasma glucose, glycemic control, insulin resistance, HOMA-IR, magnesium chloride, triglycerides, HDL cholesterol, serum magnesium
- MeSH
- humans, prediabetic state, magnesium deficiency, magnesium chloride, blood glucose, hypoglycemic agents, adult, aged, middle aged, female, male
4 autores
- Fernando Guerrero‐Romero🇲🇽Mexican Social Security Institute
- Luis E. Simental‐Mendía🇲🇽Mexican Social Security Institute
- Gabriela Hernández-Ronquillo🇲🇽Mexican Social Security Institute
- Martha Rodríguez‐Morán🇲🇽 · autor de correspondenciaMexican Social Security Institute
Resumen
El texto original del estudio, en el idioma en que se publicó.
Aim
This study evaluated the efficacy of oral magnesium supplementation in the reduction of plasma glucose levels in adults with prediabetes and hypomagnesaemia.
Methods
A total of 116 men and non-pregnant women, aged 30 to 65 years with hypomagnesaemia and newly diagnosed with prediabetes, were enrolled into a randomized double-blind placebo-controlled trial to receive either 30 mL of MgCl2 5% solution (equivalent to 382 mg of magnesium) or an inert placebo solution once daily for four months. The primary trial endpoint was the efficacy of magnesium supplementation in reducing plasma glucose levels.
Results
At baseline, there were no significant statistical differences in terms of anthropometric and biochemical variables between individuals in the supplement and placebo groups. At the end of follow-up, fasting (86.9 ± 7.9 and 98.3 ± 4.6 mg/dL, respectively; P = 0.004) and post-load glucose (124.7 ± 33.4 and 136.7 ± 23.9 mg/dL, respectively; P = 0.03) levels, HOMA-IR indices (2.85 ± 1.0 and 4.1 ± 2.7, respectively; P = 0.04) and triglycerides (166.4 ± 90.6 and 227.0 ± 89.7, respectively; P = 0.009) were significantly decreased, whereas HDL cholesterol (45.6 ± 10.9 and 46.8 ± 9.2 mg/dL, respectively; P = 0.04) and serum magnesium (1.96 ± 0.27 and 1.60 ± 0.26 mg/dL, respectively; P = 0.005) levels were significantly increased in those taking MgCl2 compared with the controls. A total of 34 (29.4%) people improved their glucose status (50.8% and 7.0% in the magnesium and placebo groups, respectively; P < 0.0005).
Conclusion
Our results show that magnesium supplementation reduces plasma glucose levels, and improves the glycaemic status of adults with prediabetes and hypomagnesaemia.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial.
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.